Lupin Limited (NSE: LUPIN)

Market Cap	972.86B
Revenue (ttm)	214.31B
Net Income (ttm)	26.26B
Shares Out	n/a
EPS (ttm)	57.41
PE Ratio	37.04
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Jul 16, 2024

Volume	626,148
Open	2,134.50
Previous Close	2,125.05
Day's Range	2,120.45 - 2,141.85
52-Week Range	1,200.15 - 2,312.00
Beta	0.59
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 5, 2025

About Lupin

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women’s health, central nerv...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1968
• Employees: 19,210
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: LUPIN

Financial Performance

In 2023, Lupin's revenue was 200.11 billion, an increase of 20.25% compared to the previous year's 166.42 billion. Earnings were 19.14 billion, an increase of 345.15%.